Mind the (Vote) Gap: Can We Get More STEM Students to the Polls?
This article is part of the magazine, "The Future of Science In America: The Election Issue," co-published by LeapsMag, the Aspen Institute Science & Society Program, and GOOD.
By the numbers, American college students who major in STEM disciplines—science, technology, engineering, and math—aren't big on voting. In fact, recent research suggests they're the least likely group of students to head to the ballot box, even as American political leaders cast doubt on the very kinds of expertise those students are developing on campus.
Worried educators say it's time for a rethink of STEM education at the college level. Armed with success stories and model courses, educators are pushing for colleagues to add relevance to STEM education—and instill a sense of civic duty—by bringing the outside world in.
"It's a matter of what's in the curriculum, how faculty spend their time. There are opportunities to weave [policy] within the curriculum," said Nancy L. Thomas, director of Tufts University's Institute for Democracy & Higher Education.
The most recent student voting numbers come from the 2018 mid-term election, when a national Democratic wave brought voters to the polls. Just over a third of STEM college students surveyed said they voted, the lowest percentage of six subject areas, according to a report from the institute at Tufts. Students in the education, social sciences, and humanities fields had the highest voting rates at 47%, 41%, and 39%, respectively.
Students across the board were much less engaged in the mid-year election of 2014, when just 28% of education students surveyed said they voted. STEM students again stood at the rear, with just 16% voting.
(The report analyzed whether more than 10 million college students at 1,031 U.S. institutions voted in 2014 and 2018. At the request of this magazine, the institute at Tufts removed non-U.S. resident students—who can't vote—from the findings to see if the results changed. Voting rates among STEM students remained among the lowest.)
Why aren't STEM students engaged in politics? "I have no reason to think that science students don't care about public policy issues," Tufts University's Thomas said. Instead, she believes that colleges fail to inspire STEM students to think beyond lectures and homework.
Enter the SENCER project—Science Education for New Civic Engagements and Responsibilities. Since 2001, the project has taught thousands of educators and students how to connect science and citizenship.
The roots of the project go back to 1990, when Rutgers University microbiologist Monica Devanas was assigned to teach a general-education class called "Biomedical Issues of AIDS." She decided to expand the curriculum to encompass insights about a wide range of societal issues. Guest speakers from the community, including a man with a grim diagnosis, talked about the disease and its spread. And Devanas's colleagues in a wide variety of disciplines offered course sections about AIDS and its role in areas such as literature, prisons and law.
"I always tried to make a connection, hoping to create scientifically engaged citizens by explaining the science to them in ways that they could understand."
When she first taught the class, 450 students signed up instead of the expected 100. Devanas, who'd only ever taught a few dozen students with a blackboard, suddenly had to figure out how to teach hundreds at once with the standard technology of the time: an overhead projector.
Devanas, who taught the hugely popular class for the next 18 years, said the course worked because it linked the AIDS epidemic, a hot topic at the time, to the outer world beyond immune cells and test tubes. "You really need to make it very personal and relevant. When you talk about treatment for AIDS or the cost of drugs: Who pays for this?" she said. "I always tried to make a connection, hoping to create scientifically engaged citizens by explaining the science to them in ways that they could understand."
How can other educators learn to create compelling courses? The SENCER website offers dozens of model classes for college and K–12 educators, all with the aim of making STEM classes relevant. An engineering course, for example, could expand a discussion about the nuts and bolts of automated vehicles into a conversation about whether the cars are a good idea in the first place, said Eliza J. Reilly, executive director of the National Center for Science and Civic Engagement, where SENCER is based.
SENCER, which is government-funded, holds regular conferences and has conducted research that supports the effectiveness of its programs. "This is an educational and intellectual project rather than a get-out-the-vote project. It's not intended to create activists. Instead, it's intended to help students understand that they have power as citizens," Reilly said.
What about long-term change? Will inspiring college students to engage with politics turn them into lifetime voters? Reilly said she's not aware of any research into whether STEM students continue to vote at lower levels after they graduate. That means there's no way to know if limited civic engagement in college translates to lifelong apathy. We also don't know if lower voting rates in college may help explain why few people with STEM backgrounds run for higher office.
There's another big unknown: If more people with STEM degrees vote, will they actually support fact-based policies and candidates who listen to science? The answer is not as obvious as it may appear. At Rutgers, professor Devanas pointed to the research of Yale University law/psychology professor Dan Kahan, who found that the most scientifically literate people in the U.S. also happen to be among those most polarized over climate change. In other words, a scientific mind may not necessarily translate to a pro-science vote.
Regardless of the ultimate choices that STEM students make at the ballot box, advocates will keep encouraging educators to connect science to the world beyond the classroom. As Tufts University's Thomas explained, "it just takes a lot of creativity and will."
[Editor's Note: To read other articles in this special magazine issue, visit the beautifully designed e-reader version.]
A new type of cancer therapy is shrinking deadly brain tumors with just one treatment
Few cancers are deadlier than glioblastomas—aggressive and lethal tumors that originate in the brain or spinal cord. Five years after diagnosis, less than five percent of glioblastoma patients are still alive—and more often, glioblastoma patients live just 14 months on average after receiving a diagnosis.
But an ongoing clinical trial at Mass General Cancer Center is giving new hope to glioblastoma patients and their families. The trial, called INCIPIENT, is meant to evaluate the effects of a special type of immune cell, called CAR-T cells, on patients with recurrent glioblastoma.
How CAR-T cell therapy works
CAR-T cell therapy is a type of cancer treatment called immunotherapy, where doctors modify a patient’s own immune system specifically to find and destroy cancer cells. In CAR-T cell therapy, doctors extract the patient’s T-cells, which are immune system cells that help fight off disease—particularly cancer. These T-cells are harvested from the patient and then genetically modified in a lab to produce proteins on their surface called chimeric antigen receptors (thus becoming CAR-T cells), which makes them able to bind to a specific protein on the patient’s cancer cells. Once modified, these CAR-T cells are grown in the lab for several weeks so that they can multiply into an army of millions. When enough cells have been grown, these super-charged T-cells are infused back into the patient where they can then seek out cancer cells, bind to them, and destroy them. CAR-T cell therapies have been approved by the US Food and Drug Administration (FDA) to treat certain types of lymphomas and leukemias, as well as multiple myeloma, but haven’t been approved to treat glioblastomas—yet.
CAR-T cell therapies don’t always work against solid tumors, such as glioblastomas. Because solid tumors contain different kinds of cancer cells, some cells can evade the immune system’s detection even after CAR-T cell therapy, according to a press release from Massachusetts General Hospital. For the INCIPIENT trial, researchers modified the CAR-T cells even further in hopes of making them more effective against solid tumors. These second-generation CAR-T cells (called CARv3-TEAM-E T cells) contain special antibodies that attack EFGR, a protein expressed in the majority of glioblastoma tumors. Unlike other CAR-T cell therapies, these particular CAR-T cells were designed to be directly injected into the patient’s brain.
The INCIPIENT trial results
The INCIPIENT trial involved three patients who were enrolled in the study between March and July 2023. All three patients—a 72-year-old man, a 74-year-old man, and a 57-year-old woman—were treated with chemo and radiation and enrolled in the trial with CAR-T cells after their glioblastoma tumors came back.
The results, which were published earlier this year in the New England Journal of Medicine (NEJM), were called “rapid” and “dramatic” by doctors involved in the trial. After just a single infusion of the CAR-T cells, each patient experienced a significant reduction in their tumor sizes. Just two days after receiving the infusion, the glioblastoma tumor of the 72-year-old man decreased by nearly twenty percent. Just two months later the tumor had shrunk by an astonishing 60 percent, and the change was maintained for more than six months. The most dramatic result was in the 57-year-old female patient, whose tumor shrank nearly completely after just one infusion of the CAR-T cells.
The results of the INCIPIENT trial were unexpected and astonishing—but unfortunately, they were also temporary. For all three patients, the tumors eventually began to grow back regardless of the CAR-T cell infusions. According to the press release from MGH, the medical team is now considering treating each patient with multiple infusions or prefacing each treatment with chemotherapy to prolong the response.
While there is still “more to do,” says co-author of the study neuro-oncologist Dr. Elizabeth Gerstner, the results are still promising. If nothing else, these second-generation CAR-T cell infusions may someday be able to give patients more time than traditional treatments would allow.
“These results are exciting but they are also just the beginning,” says Dr. Marcela Maus, a doctor and professor of medicine at Mass General who was involved in the clinical trial. “They tell us that we are on the right track in pursuing a therapy that has the potential to change the outlook for this intractable disease.”
Since the early 2000s, AI systems have eliminated more than 1.7 million jobs, and that number will only increase as AI improves. Some research estimates that by 2025, AI will eliminate more than 85 million jobs.
But for all the talk about job security, AI is also proving to be a powerful tool in healthcare—specifically, cancer detection. One recently published study has shown that, remarkably, artificial intelligence was able to detect 20 percent more cancers in imaging scans than radiologists alone.
Published in The Lancet Oncology, the study analyzed the scans of 80,000 Swedish women with a moderate hereditary risk of breast cancer who had undergone a mammogram between April 2021 and July 2022. Half of these scans were read by AI and then a radiologist to double-check the findings. The second group of scans was read by two researchers without the help of AI. (Currently, the standard of care across Europe is to have two radiologists analyze a scan before diagnosing a patient with breast cancer.)
The study showed that the AI group detected cancer in 6 out of every 1,000 scans, while the radiologists detected cancer in 5 per 1,000 scans. In other words, AI found 20 percent more cancers than the highly-trained radiologists.
Scientists have been using MRI images (like the ones pictured here) to train artificial intelligence to detect cancers earlier and with more accuracy. Here, MIT's AI system, MIRAI, looks for patterns in a patient's mammograms to detect breast cancer earlier than ever before. news.mit.edu
But even though the AI was better able to pinpoint cancer on an image, it doesn’t mean radiologists will soon be out of a job. Dr. Laura Heacock, a breast radiologist at NYU, said in an interview with CNN that radiologists do much more than simply screening mammograms, and that even well-trained technology can make errors. “These tools work best when paired with highly-trained radiologists who make the final call on your mammogram. Think of it as a tool like a stethoscope for a cardiologist.”
AI is still an emerging technology, but more and more doctors are using them to detect different cancers. For example, researchers at MIT have developed a program called MIRAI, which looks at patterns in patient mammograms across a series of scans and uses an algorithm to model a patient's risk of developing breast cancer over time. The program was "trained" with more than 200,000 breast imaging scans from Massachusetts General Hospital and has been tested on over 100,000 women in different hospitals across the world. According to MIT, MIRAI "has been shown to be more accurate in predicting the risk for developing breast cancer in the short term (over a 3-year period) compared to traditional tools." It has also been able to detect breast cancer up to five years before a patient receives a diagnosis.
The challenges for cancer-detecting AI tools now is not just accuracy. AI tools are also being challenged to perform consistently well across different ages, races, and breast density profiles, particularly given the increased risks that different women face. For example, Black women are 42 percent more likely than white women to die from breast cancer, despite having nearly the same rates of breast cancer as white women. Recently, an FDA-approved AI device for screening breast cancer has come under fire for wrongly detecting cancer in Black patients significantly more often than white patients.
As AI technology improves, radiologists will be able to accurately scan a more diverse set of patients at a larger volume than ever before, potentially saving more lives than ever.